1-[4-(trifluoromethyl)phenyl]-4-piperidinamine | 740079-32-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-[4-(trifluoromethyl)phenyl]-4-piperidinamine
• 英文别名: 4-Piperidinamine, 1-[4-(trifluoromethyl)phenyl]-；1-[4-(trifluoromethyl)phenyl]piperidin-4-amine
• CAS: 740079-32-7
• 化学式: C₁₂H₁₅F₃N₂
• mdl: MFCD09939842
• 分子量: 244.26
• InChiKey: JMYRSDQJCMLNCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[4-(trifluoromethyl)phenyl]-4-piperidinamine 、 phenyl N-(2-oxo-3H-1,3-benzoxazol-6-yl)carbamate 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 6.0h， 以59%的产率得到1-(2-oxo-3H-1,3-benzoxazol-6-yl)-3-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]urea
  参考文献：
  名称：

  EP1988077

  摘要：

  公开号：
• 作为产物：
  描述：

  2-[1-[4-(Trifluoromethyl)phenyl]piperidin-4-yl]isoindole-1,3-dione 在 乙醇 、 肼 作用下， 反应 2.0h， 以73%的产率得到1-[4-(trifluoromethyl)phenyl]-4-piperidinamine
  参考文献：
  名称：

  EP1988077

  摘要：

  公开号：

文献信息

• [EN] COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY<br/>[FR] COMPOSITION ET PROCÉDÉS D'UTILISATION DE PETITES MOLÉCULES EN TANT QUE LIGANDS DE LIAISON POUR LA MODULATION DE L'ACTIVITÉ PROPROTÉINE CONVERTASE SUBTILISINE/PROTÉINE KEXINE DE TYPE 9 (PCSK9)
  申请人：SRX CARDIO LLC

  公开号：WO2016029037A1

  公开（公告）日：2016-02-25

  This invention is related to the field of PCSK9 biology and the composition and methods of use of small molecule ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small molecule compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small molecule ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small molecule ligands that can raise LDL levels.

  这项发明涉及PCSK9生物学领域，以及用于调节PCSK9生物活性的小分子配体的组成和使用方法。具体而言，该发明提供了调节低密度脂蛋白循环水平的小分子化合物组合物，通过改变蛋白质PCSK9的构象来实现。将这些小分子配体与PCSK9结合会改变蛋白质的构象，修改PCSK9与内源性低密度脂蛋白受体之间的相互作用，并可能导致循环LDL胆固醇水平降低或增加。高LDL胆固醇水平与心脏疾病风险增加相关。低LDL胆固醇水平在其他情况下可能会有问题，比如肝功能障碍；因此，开发能够提高LDL水平的小分子配体也具有实用性。
• BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE
  申请人：Johnson Christopher Norbert

  公开号：US20090054456A1

  公开（公告）日：2009-02-26

  The present invention relates to novel benzylpiperazine derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal disorders.

  本发明涉及新型苄基哌嗪衍生物，如公式(I)化合物，其具有作为GPR38受体激动剂的活性，以及在治疗胃肠道疾病中使用这些化合物或其制剂的药物组合物。
• COMPOUNDS
  申请人：Glaxo Group Limited

  公开号：US20130317041A1

  公开（公告）日：2013-11-28

  The present invention relates to benzylpiperazine derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the preparation of medicaments suitable for the treatment of gastrointestinal disorders.

  本发明涉及苄基哌嗪衍生物，例如公式（I）的化合物，它们具有作为GPR38受体激动剂的活性，以及使用这些化合物或其制剂在制备适用于治疗胃肠道疾病的药物中的用途。
• NIROGENOUS HETEROCYCLIC DERIVATIVES SUBSTITUTED WITH CYCLIC GROUPS
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1988077A1

  公开（公告）日：2008-11-05

  It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist. A compound represented by: wherein Z is N or CR1, A1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A2 is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R1, R2, Ra, Rb, Rc and Rd are each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is -(CR3R4)m-, -CO(CR3R4)n-, -CONR5(CR3R4)n- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R3 and R4 are each independently hydrogen, halogen, hydroxy etc., and R5 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt, or a solvate thereof.

  研究发现，由式（I）代表的含氮杂环衍生物能与 NR1/NR2B 受体特异性结合，可用作 NR2B 受体拮抗剂。 由式（I）代表的化合物 其中 Z 是 N 或 CR1，A1 是任选被取代的含氮芳香族单环基团、任选被取代的含氮芳香族融合环基团等，A2 是芳香烃环基团或芳香杂环基团，各自任选具有一个取代基，R1、R2、Ra、Rb、Rc 和 Rd 各自独立地是氢、羟基等、w 是 2 或 3，t 是 1 或 2，X 是-(CR3R4)m-、-CO(CR3R4)n-、-CONR5(CR3R4)n- 等，m 是 1 至 4 的整数，n 是 0 至 4 的整数，R3 和 R4 各自独立地是氢、卤素、羟基等，R5 是氢或低级烷基、 或其药学上可接受的盐或溶液。
• Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity
  申请人：SRX CARDIO, LLC

  公开号：US10034892B2

  公开（公告）日：2018-07-31

  This invention is related to the field of PCSK9 biology and the composition and methods of use of small molecule ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small molecule compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small molecule ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small molecule ligands that can raise LDL levels.

  本发明涉及 PCSK9 生物学领域以及用于调节 PCSK9 生物活性的小分子配体的组成和使用方法。特别是，本发明提供了通过改变蛋白质 PCSK9 的构象来调节循环中低密度脂蛋白水平的小分子化合物组合物。将这些小分子配体与 PCSK9 结合可改变该蛋白的构象，改变 PCSK9 与内源性低密度脂蛋白受体之间的相互作用，并可导致循环中低密度脂蛋白胆固醇水平的降低或升高。低密度脂蛋白胆固醇水平高与心脏病风险增加有关。低密度脂蛋白胆固醇水平过低可能会对肝功能障碍等其他疾病造成困扰；因此，能提高低密度脂蛋白水平的小分子配体也很有用。